GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

The recent FDA approval for GSK's Nucala in COPD treatment and the positive recommendation for Blenrep could significantly enhance the company's revenue and earnings forecasts by expanding its ...

In 2025, GSK expects to launch five new products/line extensions, including Blenrep, depemokimab (severe asthma and CRSwNP), Nucala for COPD, Penmenvy and Blujepa. Of these, Penmenvy, Blujepa and ...

GSK itself has suggested it can drive £20bn of additional revenues, Concluding Thoughts - A Solid Quarter Of Growth & A Solidifying Outlook - May Even Offer Some Share Price Upside ...

GSK reported 4% year-on-year earnings growth (at constant currency) and core operating profit margin of 33.7%, or 30 basis points better than the same period last year. This was driven by strong ...

FTSE 100 reaction as HSBC sees profits drop, Nationwide launches benefits line - Stock market news and latest business and ...

For the period 2021-2026, GSK now expects sales to grow more than 7% on a CAGR (Compound Annual Growth Rate) basis and adjusted operating profit to increase more than 11%, on the same basis.

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence. Meanwhile, the Committee for Medicinal Products for Human Use recommended Blenrep ...